Appendix E. Evidence Tables

Evidence Table 1. Characteristics of included trials

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year**  **Country** | **Group Sample Size** | Study Design  Study Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Beatty, 20101  Australia | Randomized: 49  G1: 25  G2: 24  Analyzed: 49  G1: 25  G2: 24 | RCT  Outpatient, urban public hospitals  6 months | PSS-SR  Baseline, 3 months, & 6 months | Academic |
| Bryant, 20082  Australia | Randomized: 90  G1: 30  G2: 30  G3: 30  ITT Analyzed: 90  G1: 30  G2: 30  G3: 30  Analyzed (Completers Analysis): 69  G1: 25  G2: 23  G3: 21 | RCT  Outpatient, special MH  6 months | CAPS-2,  Baseline, 5 weeks, 6 months | Government |
| Bryant, 20033  Australia | Randomized: 24  G1: 12  G2: 12  Analyzed: 24  G1: 12  G2: 12 | RCT  Inpatient  6 months | CAPS-2 & IES  Baseline, 1 week, & 6 months | Government |
| Bryant, 19984 \*  Australia  \*Study design changed from NRCT to RCT | Randomized: 24  G1: 12  G2: 12  Analyzed: 24  G1: 12  G2: 12 | RCT  Outpatient, special MH  6 months | IES  Baseline  CIDI PTSD & IES  6 weeks & 6 months | Government |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year  Country | Group Sample Size | Study Design  Study Setting  Study Duration | Primary Outcome & Timing of Assessment | Funding Source |
| Bryant, 20055  Australia | Randomized: 87  G1: 33  G2: 30  G3: 24  ITT Analyzed: 87  G1: 33  G2: 30  G3: 24  Analyzed (Completers Analysis): 69  G1: 24  G2: 23  G3: 22 | RCT  Outpatient, special MH  6 months | IES  Baseline  IES & CAPS-2  5 weeks, 6 months | Government |
| Campfield, 20016  Australia | Randomized: 77  G1: 36  G2: 41  Analyzed: 77  G1: 36  G2: 41 | RCT  Outpatient, special MH  2 weeks | PDS  Debriefing, 2 days post debriefing, 4 days post-debriefing, 2 weeks post-trauma | NR |
| Gamble, 20057  Australia | Randomized: 103  G1: 50  G2: 53  Analyzed (Completers Analysis): 103  G1: 50  G2: 53 | RCT  Inpatient and Home  3 months | MINI-PTSD  4-6 weeks, 3 months | Foundation and academic |
| Melnyk, 20048  NA | Randomized: 174  G1: 90  G2: 84  ITT Analyzed: 174  G1: 90  G2: 84  Analyzed (Completers Analysis): 163  G1: 87  G2: 76 | RCT  Inpatient  12 months | Post-Hospital Stress Index for Parents (post treatment)  1 month, 3 months, 6 months, & 12 months | Government |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year**  **Country** | **Group Sample Size** | **Study Design**  **Study Setting**  **Study Duration** | Primary Outcome & Timing of Assessment | Funding Source |
| Mulligan, 20129  United Kingdom | Randomized: 2523  G1: 1144  G2: 1379  Analyzed 4-6 month ITT: 2443  G1: 1108  G2: 1335  Analyzed 4-6 month completers analysis:  G1: 797  G2: 819 | RCT  Outpatient, military  4-6 months | PCL-C  Baseline, 4-6 months | NR |
| O'Donnell, 201210  Australia | Randomized: 46  G1: 24  G2: 22  Analyzed 6 & 12 month ITT: 46  G1: 24  G2: 22  Analyzed (6 month completers analysis): 42  G1: 22  G2: 20  Analyzed 12 month completers analysis): 31  G1: 19  G2: 12 | RCT  Outpatient, special MH  12 months | CAPS  Baseline, 6 months, 12 months | Government and Foundation |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year**  **Country** | **Group Sample Size** | **Study Design**  **Study Setting**  **Study Duration** | Primary Outcome & Timing of Assessment | Funding Source |
| Rose, 199911  United Kingdom | Randomized: 157  G1: 54  G2: 52  G3: 51  Analyzed (completers analysis): 92  G1: NR  G2: NR  G3: NR  ITT Analyzed: 157  G1: 54  G2: 52  G3: 51 | RCT  Community  6 months a | PSS-SR & IES  Baseline, 6 monthsa | Government |
| Rothbaum, 201212  United States | Randomized: 137  G1: 69  G2: 68  Analyzed 4 weeks ITT:b 137  G1: 69  G2: 68 | RCT  Inpatient and outpatient  4 weeks b | PDS & PSS-I  Baseline, 4 weeks b | Government |
| Ryding, 200413  Sweden | Randomized:162  G1: 89  G2: 73  Analyzed: 147  G1: 82  G2: 65 | RCT  Inpatient  6 months | IES  6 months | Foundation/non-profit |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year**  **Country** | **Group Sample Size** | **Study Design**  **Study Setting**  **Study Duration** | Primary Outcome & Timing of Assessment | Funding Source |
| Shalev, 201114  Israel | Randomized: 242  G1: 63  G2: 40  G3: 23  G4: 23  G5: 93  Analyzed: 180  G1: 52  G2: 35  G3: 19  G4: 17  G5: 57 | RCT  Outpatient, special MH  9 months | CAPS  Baseline, 5 months, & 9 months | Foundation, Pharmaceutical, and Government |
| Sijbrandij, 200615  Netherlands | Randomized: 236  G1: 76  G2: 79  G3: 81  ITT Analyzed: 236  G1: 76  G2: 79  G3: 81 | RCT  Outpatient, special MH  6 Months | SI-PTSD  Baseline, 2 weeks, 6 weeks, & 6 months | NR |
| Treggiari, 200916  Switzerland | Randomized: 137  G1: 69  G2: 68  Analyzed:129  G1: 65  G2: 64 | RCT  Inpatient  4 weeks | PCL & IES-R  Baseline & 4 weeks | Foundation |
| Weis, 200617  Germany | Randomized: 36  G1: NR  G2: NR  Analyzed: 28  G1: 14  G2: 14 | RCT  Inpatient  6 months | PTSS-10  6 months | NR |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year**  **Country** | **Group Sample Size** | **Study Design**  **Study Setting**  **Study Duration** | Primary Outcome & Timing of Assessment | Funding Source |
| Wong, Under review18  United States | Randomized: 99  G1: 52  G2: 47  Analyzed 1 month completers analysis: 79  G1: 42  G2: 37 | RCT  Inpatient  1 month | PCL  Baseline, 1 month | NR |
| Zatzick, In press19  United States | Randomized: 207  G1: 104  G2: 103  Analyzed 1 month ITT: 207  G1: 104  G2: 103  Analyzed 1 month completers analysis: 176  G1: 86  G2: 90  Analyzed 3 months ITT: 207  G1: 104  G2: 103  Analyzed 3 months completers analysis: 164  G1: 81  G2: 83  Analyzed 6 months ITT: 207  G1: 104  G2: 103  Analyzed 6 months completers analysis: 162  G1: 86  G2: 76 | RCT  Inpatient and outpatient  12 months | CAPS & PCL-C  Baseline, 1 month, 3 months, 6 months, 9 months, & 12 months | Government |

Evidence Table 1. Characteristics of included trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year**  **Country** | **Group Sample Size** | **Study Design**  **Study Setting**  **Study Duration** | Primary Outcome & Timing of Assessment | Funding Source |
| Zatzick, In press19  (continued) | Analyzed 9 months ITT: 207  G1: 104  G2: 103  Analyzed 9 months completers analysis: 155  G1: 83  G2: 72  Analyzed 12 months ITT: 207  G1: 104  G2: 103  Analyzed 12 months completers analysis: 167  G1: 87  G2: 80 |  |  |  |

a Followup was also conducted at 11 months, but we rated all 11-month outcomes as having a high risk of bias because of high overall attrition (>30%) at that timepoint and therefore do not report any of those outcomes.

b Followup was also conducted at 12 weeks, but we rated all 12-week outcomes as having a high risk of bias because of high overall attrition (>30%) at that timepoint and therefore do not report any of those outcomes.

Abbreviations: CAPS = Clinician Administered PTSD Scale; CAPS-2 = Clinician Administered PTSD Scale-2; CIDI PTSD = Composite International Diagnostic Interview PTSD module; G = group; IES = Impact of Event Scale; IES-R = Impact of Event Scale-Revised; ITT = intent-to-treat analysis; MH = mental health; MINI-PTSD = Mini-International Neuropsychiatric Interview-Post-Traumatic Stress Disorder Module; NA = not applicable; NR = not reported; NRCT = nonrandomized controlled trial; PCL = Posttraumatic Stress Disorder Checklist; PCL-C = Posttraumatic Stress Disorder Checklist-Civilian Version; PDS = Posttraumatic Stress Diagnostic Scale; PTSD = posttraumatic stress disorder; PSS-I = Posttraumatic Stress Scale-Interview version; PSS-SR = Posttraumatic Stress Scale-Self-Report version; PTSS-10 = Posttraumatic Stress Symptom 10 Question Inventory; RCT = randomized controlled trial; SI-PTSD = Structured Interview for PTSD